Ceritinib (Zykadia®) is a targeted therapy drug used to treat non-small cell lung cancer (NSCLC).
It is only used if tests show the cancer cells have a gene change, also called a gene mutation. This change affects a gene called anaplastic lymphoma kinase (ALK). NSCLC that has this gene change is called ALK-positive NSCLC.
Your doctor will talk to you about this treatment and its possible side effects before you agree (consent) to have treatment.